相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phagocytosis by an HIV antibody is associated with reduced viremia irrespective of enhanced complement lysis
David A. Spencer et al.
NATURE COMMUNICATIONS (2022)
Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment
Jiewen Wang et al.
FRONTIERS IN IMMUNOLOGY (2022)
Prolonged viral suppression with anti-HIV-1 antibody therapy
Christian Gaebler et al.
NATURE (2022)
A functional map of HIV-host interactions in primary human T cells
Joseph Hiatt et al.
NATURE COMMUNICATIONS (2022)
An exploration of how broadly neutralizing antibodies might induce HIV remission: the 'vaccinal' effect
Timothy Tipoe et al.
CURRENT OPINION IN HIV AND AIDS (2022)
Global post-translational modification profiling of HIV-1-infected cells reveals mechanisms of host cellular pathway remodeling
Jeffrey R. Johnson et al.
CELL REPORTS (2022)
HIV-1 Reservoir Persistence and Decay: Implications for Cure Strategies
Edward F. Kreider et al.
CURRENT HIV/AIDS REPORTS (2022)
A guide to: generation and design of nanobodies
Serge Muyldermans
FEBS JOURNAL (2021)
Accelerated Clearance and Degradation of Cell-Free HIV by Neutralizing Antibodies Occurs via FcγRIIb on Liver Sinusoidal Endothelial Cells by Endocytosis
James M. Turman et al.
JOURNAL OF IMMUNOLOGY (2021)
Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies
Gihoon You et al.
VACCINES (2021)
Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses
Sham Nambulli et al.
SCIENCE ADVANCES (2021)
Productive HIV infection in astrocytes can be established via a nonclassical mechanism
Guan-Han Li et al.
AIDS (2020)
Broadly neutralizing antibodies for the treatment and prevention of HIV infection
Marina Caskey
CURRENT OPINION IN HIV AND AIDS (2020)
Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention
Kathryn E. Stephenson et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 38 (2020)
Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies
Daniel Wrapp et al.
CELL (2020)
The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies
Lillian B. Cohn et al.
CELL HOST & MICROBE (2020)
Broadly neutralizing antibodies and vaccine design against HIV-1 infection
Qian Wang et al.
FRONTIERS OF MEDICINE (2020)
Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2
Jianbo Dong et al.
SCIENTIFIC REPORTS (2020)
Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial
Trevor A. Crowell et al.
LANCET HIV (2019)
Bispecific antibodies: a mechanistic review of the pipeline
Aran F. Labrijn et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Bispecific antibodies: Potential immunotherapies for HIV treatment
Giulia Fabozzi et al.
METHODS (2019)
Super Potent Bispecific Llama VHH Antibodies Neutralize HIV via a Combination of gp41 and gp120 Epitopes
Nika M. Strokappe et al.
ANTIBODIES (2019)
Combination therapy with anti-HIV-1 antibodies maintains viral suppression
Pilar Mendoza et al.
NATURE (2018)
Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals
Yotam Bar-On et al.
NATURE MEDICINE (2018)
Bispecific antibodies for viral immunotherapy
Elisabeth K. Nyakatura et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2017)
Early antibody therapy can induce long-lasting immunity to SHIV
Yoshiaki Nishimura et al.
NATURE (2017)
Camelid Single-Domain Antibodies: Historical Perspective and Future Outlook
Mehdi Arbabi-Ghahroudi
FRONTIERS IN IMMUNOLOGY (2017)
Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs
Diane L. Bolton et al.
JOURNAL OF VIROLOGY (2016)
Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency
Stylianos Bournazos et al.
CELL (2016)
Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity
Yaoxing Huang et al.
CELL (2016)
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption
Johannes F. Scheid et al.
NATURE (2016)
A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges
Rajeev Gautam et al.
NATURE (2016)
Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption
K. J. Bar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Elimination of HIV-1-infected cells by broadly neutralizing antibodies
Timothee Bruel et al.
NATURE COMMUNICATIONS (2016)
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117
Marina Caskey et al.
NATURE (2015)
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection
Rebecca M. Lynch et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
EGF receptor trafficking: consequences for signaling and cancer
Alejandra Tomas et al.
TRENDS IN CELL BIOLOGY (2014)
HIV entry: a game of hide-and-fuse?
Gregory B. Melikyan
CURRENT OPINION IN VIROLOGY (2014)
Molecular Evolution of Broadly Neutralizing Llama Antibodies to the CD4-Binding Site of HIV-1
Laura E. McCoy et al.
PLOS PATHOGENS (2014)
Straightforward Selection of Broadly Neutralizing Single-Domain Antibodies Targeting the Conserved CD4 and Coreceptor Binding Sites of HIV-1 gp120
Julie Matz et al.
JOURNAL OF VIROLOGY (2013)
HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice
Joshua A. Horwitz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Structural Evaluation of EGFR Inhibition Mechanisms for Nanobodies/VHH Domains
Karl R. Schmitz et al.
STRUCTURE (2013)
A gp41 MPER-specific Llama VHH Requires a Hydrophobic CDR3 for Neutralization but not for Antigen Recognition
David Lutje Hulsik et al.
PLOS PATHOGENS (2013)
Human immunodeficiency virus and heparan sulfate: from attachment to entry inhibition
Bridgette J. Connell et al.
FRONTIERS IN IMMUNOLOGY (2013)
Llama Antibody Fragments Have Good Potential for Application as HIV Type 1 Topical Microbicides
Andrea Gorlani et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2012)
HIV therapy by a combination of broadly neutralizing antibodies in humanized mice
Florian Klein et al.
NATURE (2012)
Llama Antibody Fragments Recognizing Various Epitopes of the CD4bs Neutralize a Broad Range of HIV-1 Subtypes A, B and C
Nika Strokappe et al.
PLOS ONE (2012)
A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth
Rob C. Roovers et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Llama-Derived Single Domain Antibodies to Build Multivalent, Superpotent and Broadened Neutralizing Anti-Viral Molecules
Anna Hultberg et al.
PLOS ONE (2011)
HIV Enters Cells via Endocytosis and Dynamin-Dependent Fusion with Endosomes
Kosuke Miyauchi et al.
CELL (2009)
Llama-Derived Single-Domain Intrabodies Inhibit Secretion of Hepatitis B Virions in Mice
Benedikte Serruys et al.
HEPATOLOGY (2009)
EGF induces coalescence of different lipid rafts
Erik G. Hofman et al.
JOURNAL OF CELL SCIENCE (2008)
Llama Antibody Fragments with Cross-Subtype Human Immunodeficiency Virus Type 1 (HIV-1)-Neutralizing Properties and High Affinity for HIV-1 gp120
Anna Forsman et al.
JOURNAL OF VIROLOGY (2008)
Identification of host proteins required for HIV infection through a functional genomic screen
Abraham L. Brass et al.
SCIENCE (2008)
The Achilles heel of the Trojan horse model of HIV-1 trans-infection
Marielle Cavrois et al.
PLOS PATHOGENS (2008)
Virus-like particles - universal molecular toolboxes
Christine Ludwig et al.
CURRENT OPINION IN BIOTECHNOLOGY (2007)
Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR Nanobodies
Rob C. Roovers et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Increased heterologous protein production by Saccharomyces cerevisiae growing on ethanol as sole carbon source
Teun van de Laar et al.
BIOTECHNOLOGY AND BIOENGINEERING (2007)
Distribution and three-dimensional structure of AIDS virus envelope spikes
Ping Zhu et al.
NATURE (2006)
Antibody vs. HIV in a clash of evolutionary titans
DR Burton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Inhibition of lysosome and proteasome function enhances human immunodeficiency virus type 1 infection
BDL Wei et al.
JOURNAL OF VIROLOGY (2005)
Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus
BL Fredericksen et al.
JOURNAL OF VIROLOGY (2002)
分享论文
